❮ Back to Researchers

Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Email: Lawrence.Leiter@unityhealth.to
Tel: 416-867-7441

Research Programs

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Ayoub-Charette, S, McGlynn, ND, Lee, D, Khan, TA, Blanco Mejia, S, Chiavaroli, L et al.. Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study. Nutrients. 2023;15 (5):. doi: 10.3390/nu15051238. PubMed PMID:36904237 PubMed Central PMC10005063.
  2. Schechter, M, Wiviott, SD, Raz, I, Goodrich, EL, Rozenberg, A, Yanuv, I et al.. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023; :. doi: 10.1016/S2213-8587(23)00009-8. PubMed PMID:36878239 .
  3. Zelniker, TA, Wiviott, SD, Mosenzon, O, Goodrich, EL, Jarolim, P, Cahn, A et al.. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. JAMA Cardiol. 2023; :. doi: 10.1001/jamacardio.2023.0019. PubMed PMID:36857035 PubMed Central PMC9979005.
  4. Chiavaroli, L, Cheung, A, Ayoub-Charette, S, Ahmed, A, Lee, D, Au-Yeung, F et al.. Important food sources of fructose-containing sugars and adiposity: A systematic review and meta-analysis of controlled feeding trials. Am J Clin Nutr. 2023; :. doi: 10.1016/j.ajcnut.2023.01.023. PubMed PMID:36842451 .
  5. Khan, TA, Field, D, Chen, V, Ahmad, S, Mejia, SB, Kahleová, H et al.. Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2023;46 (3):643-656. doi: 10.2337/dc22-1024. PubMed PMID:36812419 PubMed Central PMC10020027.
  6. Krishnaraj, A, Bakbak, E, Teoh, H, Bhatt, DL, Quan, A, Puar, P et al.. Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease. Med (N Y). 2023;4 (2):130-138.e1. doi: 10.1016/j.medj.2022.12.008. PubMed PMID:36630964 .
  7. Ray, KK, Troquay, RPT, Visseren, FLJ, Leiter, LA, Scott Wright, R, Vikarunnessa, S et al.. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11 (2):109-119. doi: 10.1016/S2213-8587(22)00353-9. PubMed PMID:36620965 .
  8. Yale, JF, Roborel de Climens, A, Aggarwal, N, Dex, T, Gerstein, HC, Harris, S et al.. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes Ther. 2023;14 (2):377-386. doi: 10.1007/s13300-022-01353-6. PubMed PMID:36574199 PubMed Central PMC9943797.
  9. Koenig, W, Conde, LG, Landmesser, U, Leiter, LA, Ray, KK, Schwartz, GG et al.. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2022; :. doi: 10.1007/s10557-022-07413-0. PubMed PMID:36550348 .
  10. Pollack, R, Raz, I, Wiviott, SD, Goodrich, EL, Murphy, SA, Yanuv, I et al.. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care. 2023;46 (1):156-164. doi: 10.2337/dc22-1318. PubMed PMID:36399721 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto